Sangamo Therapeutics (NASDAQ:SGMO) Q2 results:
Revenues down 18% to $17.5M primarily due to a change in estimate resulting from the expansion of its agreement with Pfizer in hemophilia A.
Net loss: ($30.3M); loss/share: ($0.26).
Shares down 1% after hours.
Previously: Sangamo Therapeutics EPS beats by $0.08, beats on revenue(Aug. 7)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.